Molecular subtyping of endometrial cancer via a simplified one-step NGS classifier, ARID1A and ZFHX4 mutations help further subclassify CNL/MSI-H patients.

Summary: Doctors usually need a lot of time and tissue samples to figure out the exact type of uterine cancer a patient has. This study tested a faster, one-step DNA test to do the same job using a method called Next-Generation Sequencing. By testing 233 patients, researchers successfully sorted the cancers into four main groups, each with very different survival chances. For example, one group had a 100% survival rate over 10 years, while another had a much lower chance. They also found two specific gene changes (ARID1A and ZFHX4) that help warn doctors if a patient might have a tougher fight ahead. This new, simplified test saves time, uses less tissue, and helps doctors plan the best treatment for each patient.